Related Experiment Videos

Nitrosamine-induced lung carcinogenesis and Ca2+/calmodulin antagonists

H M Schüller1

  • 1Department of Pathobiology, University of Tennessee, Knoxville 37901.

Cancer Research
|May 1, 1992
PubMed

Insights

Tobacco carcinogens like nitrosamines activate nicotinic receptors, promoting lung cancer cell growth. A novel compound, B859-35, shows promise in inhibiting neuroendocrine lung tumor proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell membrane receptors and signal transduction pathways are implicated in tobacco-related lung carcinogenesis.
  • Nicotine and tobacco-specific nitrosamines are potential molecular targets for lung cancer therapy.

Purpose of the Study:

  • To review recent data on molecular targets in tobacco-related lung carcinogenesis.
  • To explore the therapeutic potential of novel compounds against neuroendocrine lung tumors.

Main Methods:

  • Review of existing literature on nitrosamine binding to nicotinic cholinergic receptors.
  • In vitro and in vivo studies on the antiproliferative effects of dihydropyridine derivative B859-35 on lung tumor cells.
  • Investigation of B859-35's mechanism of action, including inhibition of Ca2+/calmodulin and protein kinase C.

Main Results:

  • N-nitrosodiethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bind to nicotinic cholinergic receptors in hamster lung.
  • Nitrosamine and nicotine binding stimulates proliferation of human lung carcinoid cells in vitro.
  • B859-35 exhibits selective antiproliferative effects on neuroendocrine lung tumor cells.

Conclusions:

  • Chronic stimulation of nicotinic receptors by nicotine and nitrosamines may drive neuroendocrine lung tumor development in smokers.
  • B859-35's inhibition of key signal transduction pathways suggests its potential as a therapeutic agent for neuroendocrine lung cancers.

Related Concept Videos